Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-768-7 | CAS number: 7723-14-0
Endpoint summary
Administrative data
Description of key information
NOAEL, Rat, Oral (Gavage), 5 Weeks = 1000 mg/kg bw/day
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A combined repeat dose toxicity study and reproductive / developmental toxicity screening study in rats was conducted (Huntingdon Life Sciences, 2012) to assess the effect of Fe3P on rats following repeated oral administration. The study was conducted according to OECD test guideline 422, and in compliance with GLP.
Male and female rats were administered Fe3P by oral gavage for five weeks (males, and toxicity phase females), or for two weeks before mating, during mating and gestation, and until day six of lactation (main phase females). The dose groups were 100, 300, and 1000 mg/kg/day, and a concurrent control group was administered with untreated vehicle.
No clinical signs of toxicity were observed, and no animals died during the administration period. No changes in bodyweight gains, food consumption, haematology, clinical chemistry, organ weights, macropathology or hisopathology were observed which could be attributed to treatment with the test compound.
It was conclued that Fe3P was well tolerated and that no signs of systemic toxicity had been seen in rats when administered up to 1000 mg/kg bodyweight/day for up to 5 weeks. On this basis, the No Observed Adverse Effect Level (NOAEL) in rats is 1000 mg/kg/day.
Justification for classification or non-classification
In the above-mentioned subacute study (Huntingdon Life Sciences, 2012), no signs of systemic toxicity were observed following repeat oral administration of Fe3P to rats for up to 5 weeks; there is therefore no basis on which to classify Fe3P for Specific Target Organ Toxicity (repeated exposure).
No data are available regarding repeated exposure to Fe3P by dermal or inhaled routes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
